公开(公告)号：US5489615A

公开(公告)日：1996-02-06

申请号：US171471

申请日：1993-12-22

申请人： Margit Nagy nee Kricsfalussy ,  Maria Hoor ,  Maria Szeli nee Seger ,  Janos Egri ,  Rita Balazs ,  Marta Kovacs ,  Gyula Sebestyen ,  Antal Mosonyi

发明人： Margit Nagy nee Kricsfalussy ,  Maria Hoor ,  Maria Szeli nee Seger ,  Janos Egri ,  Rita Balazs ,  Marta Kovacs ,  Gyula Sebestyen ,  Antal Mosonyi

IPC分类号： C07D417/12 ,  A61K9/00 ,  A61K9/06 ,  A61K31/54 ,  A61K31/5415 ,  A61K47/00 ,  A61K47/08 ,  A61K47/14 ,  A61K47/32 ,  A61P17/00 ,  A61P29/00

CPC分类号： A61K9/0014 ,  A61K31/54 ,  Y10S514/969

摘要： A pharmaceutical ointment is disclosed containing to 10 percent by mass of micronized piroxicam, 15 to 30 percent by mass of hydrophobic carrier(s), 60 to 75 percent by mass of water, 0.1 to 10 percent by mass of additive(s), and 2 to 5 percent by mass of emulsifiers selected from (i) a poly(ethylene glycol) alkyl or alkenyl ether and (ii) a sorbitane ester of a fatty acid or an oleic acid in a mass ratio of 3:1 to 1:3. The ointment is free from skin irritative action and has local antiphlogistic activity. In addition, a process for preparing he pharmaceutical ointment is provided.

摘要翻译： 公开了一种药膏，其含有10质量％的微粉化吡罗昔康，15〜30质量％的疏水性载体，60〜75质量％的水，0.1〜10质量％的添加剂，以及 选自（i）聚（乙二醇）烷基或链烯基醚的乳化剂为2〜5质量％，（ii）脂肪酸或油酸的山梨糖醇酯的质量比为3:1〜1:3 。 软膏无皮肤刺激作用，具有局部消炎作用。 此外，还提供了制备药物软膏的方法。

公开(公告)号：US5169847A

公开(公告)日：1992-12-08

申请号：US797963

申请日：1991-11-26

申请人： Margit Nagy nee Kricsfalussy ,  Hedvig Szauder nee Lauko ,  Janos Egri

发明人： Margit Nagy nee Kricsfalussy ,  Hedvig Szauder nee Lauko ,  Janos Egri

IPC分类号： A61K9/08 ,  A61K9/00 ,  A61K31/54 ,  A61K31/5415 ,  A61K47/16 ,  A61K47/18 ,  A61K47/22 ,  A61P27/02 ,  A61P29/00

CPC分类号： A61K9/0048 ,  A61K31/54 ,  A61K47/183 ,  A61K9/0019 ,  Y10S514/912

摘要： The invention relates to novel pyroxycam solutions of increased stability and without tissue-damaging effect, particularly to solutions which can be used as injectable solutions or eye drops.The solution according to the invention comprises 1 to 5% by mass of 4 hydroxy- 2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide, 0.5 to 5.0 % by mass of sodium glycinecarboxylate as well as 0.5 to 12% by mass of additive(s).The invention further relates to a process for the preparation of the above solutions.

摘要翻译： 本发明涉及具有增加的稳定性和不具有组织损伤作用的新型热解胶溶液，特别涉及可用作可注射溶液或滴眼剂的溶液。 根据本发明的溶液包含1至5质量％的4-羟基-2-甲基-N-（2-吡啶基）-2H-1,2-苯并噻嗪-3-甲酰胺-1,1-二氧化物，0.5至5.0 质量％的甘氨酸羧酸钠以及0.5〜12质量％的添加剂。 本发明还涉及制备上述溶液的方法。

公开(公告)号：US4871728A

公开(公告)日：1989-10-03

申请号：US232162

申请日：1988-08-12

申请人： Gyula Sebestyen ,  Istvan Simonyi ,  Gizelle Miholics ,  Marta Kovacs ,  Frigyes Gorgenyi ,  Marton Fekete ,  Pal Vago ,  Istvan Seres ,  Janos Egri ,  Maria Szeli

发明人： Gyula Sebestyen ,  Istvan Simonyi ,  Gizelle Miholics ,  Marta Kovacs ,  Frigyes Gorgenyi ,  Marton Fekete ,  Pal Vago ,  Istvan Seres ,  Janos Egri ,  Maria Szeli

IPC分类号： A61K31/555 ,  A61P31/04 ,  A61P31/10 ,  C07D215/30

CPC分类号： C07D215/30

摘要： The invention refers to a novel pharmaceutical composition having especially antimycotic activity and comprising the zinc complex of 5-chloro-7-iodo-8-hydroxyquinoline of formula (I) ##STR1## and one or more pharmaceutically acceptable carriers. The pharmaceutical composition of the invention can be used for the effective treatment of mycotic infections on the skin surface, mucous membranes or nails.The complex of formula (I) is prepared by reacting a solution of an alkali metal salt of 5-chloro-7-iodo-8-hydroxyquinoline with a solution containing an excess of an inorganic or organic zinc salt or a zinc complex having a lower stability constant than that of the complex of formula (I) and separating the product precipitated.

摘要翻译： 本发明涉及具有特异性抗真菌活性的新型药物组合物，其包含式（I）的5-氯-7-碘-8-羟基喹啉与一种或多种药学上可接受的载体的锌络合物。 本发明的药物组合物可用于有效治疗皮肤表面，粘膜或指甲上的霉菌感染。 式（I）的络合物通过使5-氯-7-碘-8-羟基喹啉的碱金属盐溶液与含有过量的无机或有机锌盐的溶液或具有较低的 稳定常数比式（I）的络合物和分离产物沉淀。

公开(公告)号：US4680315A

公开(公告)日：1987-07-14

申请号：US689222

申请日：1985-01-07

申请人： Denes Bezzegh ,  Karoly Magyar ,  Jozsef Kelemen ,  Gabor Zalai ,  Attila Mandi ,  Janos Egri

发明人： Denes Bezzegh ,  Karoly Magyar ,  Jozsef Kelemen ,  Gabor Zalai ,  Attila Mandi ,  Janos Egri

IPC分类号： A23K1/16 ,  A23K1/175 ,  A61K31/047 ,  A61K47/02 ,  C07C29/94 ,  A61K31/045

CPC分类号： C07C29/94 ,  A23K20/105 ,  A23K20/24 ,  A23K20/28 ,  A61K31/047 ,  A61K47/02

摘要： The invention refers to a powder mixture having a high propylene glycol content and a process for the preparation thereof. The powder mixture consists of 25 to 75 percent by weight of propylene glycol and 75 to 25 percent by weight of magnesium oxide and/or magnesium peroxide and/or magnesium carbonate as a solid carrier(s). The powder mixture can be treated as a solid powder and it does not deliquesce in the air even when stored for a long time. The mixture can be used as solid propylene glycol in dietetic products for calf, piglet and lamb, in pharmaceutical compositions for the treatment of ketosis and in other pharmaceutical compositions for veterinary use.

摘要翻译： 本发明涉及具有高丙二醇含量的粉末混合物及其制备方法。 粉末混合物由25至75重量％的丙二醇和75至25重量％的氧化镁和/或氧化镁和/或碳酸镁作为固体载体组成。 粉末混合物可以作为固体粉末处理，即使长时间储存​​也不会在空气中潮解。 在用于治疗酮症的药物组合物和用于兽医用途的其它药物组合物中，该混合物可用作小牛，小猪和羔羊的饮食产品中的固体丙二醇。

公开(公告)号：US20090281143A1

公开(公告)日：2009-11-12

申请号：US12331890

申请日：2008-12-10

申请人： Peter Literati Nagy ,  Zoltan Szilvassy ,  Kalman Tory ,  Attila Kolonics ,  Sandor Bernath ,  Laszlo Vigh ,  Jesse Roth ,  G. Alexander Fleming ,  Michael Brownstein ,  Janos Egri

发明人： Peter Literati Nagy ,  Zoltan Szilvassy ,  Kalman Tory ,  Attila Kolonics ,  Sandor Bernath ,  Laszlo Vigh ,  Jesse Roth ,  G. Alexander Fleming ,  Michael Brownstein ,  Janos Egri

IPC分类号： A61K31/4545 ,  A61P3/04

CPC分类号： A61K31/454 ,  A61K31/4545 ,  A61K45/06 ,  A61K2300/00

摘要： O-(3-Piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime or a pharmaceutically acceptable acid addition salt thereof is administered to patients suffering from overweight or obesity and treated with a cannabinoid CB1 receptor antagonist such as rimonabant to reduce overweight or obesity and, preferably, reduce one or more unfavourable psychiatric side effects of the cannabinoid CB1 receptor antagonist.

摘要翻译： 向患有超重或肥胖症的患者施用O-（3-哌啶子基-2-羟基-1-丙基） - 烟酰胺偕胺肟或其药学上可接受的酸加成盐，并用大麻素CB1受体拮抗剂如利莫那班治疗以减少超重或 肥胖症，并且优选地减少大麻素CB1受体拮抗剂的一种或多种不利的精神病学副作用。

公开(公告)号：US4396877A

公开(公告)日：1983-08-02

申请号：US246477

申请日：1981-03-23

申请人： Janos Egri ,  Gyoorgy Kucsera

发明人： Janos Egri ,  Gyoorgy Kucsera

IPC分类号： H02P7/00 ,  H02P7/292 ,  H05B7/144 ,  H02P5/40

CPC分类号： H05B7/144 ,  H02P7/05 ,  H02P7/293 ,  Y02P10/256 ,  Y02P10/259

摘要： A reversible electric drive with bidirectional back-current brakes fed by a rectifier supplied from a pair of A.C. power lines for a D.C. motor having two directions of rotation and two poles, comprises a control rectifier bridge for each direction of rotation, each bridge having two branches each containing a diode which is common to both bridges, a shunt resistor for each direction of rotation which is identical with a braking resistor for each other direction of rotation connected in series with the motor for each bridge, each bridge having two other branches each containing a rectifier thyristor with cathodes of each rectifier thyristor connected to a common point. The common point of each bridge is connected to one of the poles of the motor with a control thyristor connected to each common point in series with each respective shunt resistor of each bridge and connected to each other by a connecting point. The common diode is connected to the connecting point, and a braking thyristor is provided between a connecting point of each braking thyristor is provided between a connecting point of each shunt resistor and its respective control thyristor and the common points respectively.

摘要翻译： 具有由用于具有两个旋转方向和两极方向的直流电动机的一对AC电力线提供的整流器馈送的具有双向逆流制动器的可逆电驱动器包括用于每个旋转方向的控制整流桥，每个桥具有两个 每个桥具有两个桥两个共同的二极管，每个旋转方向的分流电阻器，与用于每个桥接器与电动机串联的每个其他旋转方向的制动电阻器相同，每个桥接器具有两个其他分支 包含整流晶闸管，其每个整流晶闸管的阴极连接到公共点。 每个桥的公共点连接到电动机的极之一，控制晶闸管连接到每个公共点，每个公共点与每个桥的每个相应的分流电阻串联，并通过连接点彼此连接。 公共二极管连接到连接点，并且在每个制动晶闸管的连接点分别设置在每个分流电阻器的连接点及其相应的控制晶闸管和公共点之间的制动晶闸管。

公开(公告)号：US4871722A

公开(公告)日：1989-10-03

申请号：US158757

申请日：1988-02-22

申请人： Karoly Magyar ,  Janos Varga ,  Ferenc Simon ,  Hedvig Szauder nee Lauko ,  Pal Fekete ,  Attila Romvary ,  Janos Egri ,  Katalin Zukovics nae Someg

发明人： Karoly Magyar ,  Janos Varga ,  Ferenc Simon ,  Hedvig Szauder nee Lauko ,  Pal Fekete ,  Attila Romvary ,  Janos Egri ,  Katalin Zukovics nae Someg

IPC分类号： A23K1/16 ,  A23K1/18 ,  A61K31/505 ,  A61K31/635 ,  A61P31/04 ,  C07D239/49 ,  C07D239/52

CPC分类号： A61K31/635 ,  G05B2219/36242

摘要： The invention relates to a synergistic veterinary composition and/or a fodder premix useful for preventing or curing bacterial, fungal and protozoic infection particularly occurring at poultry species. Furthermore the invention relates to a process for preparing same. The composition or premix contains 1 to 100 parts by mass of 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine and/or 1 to 100 parts by mass of 2,4-diamino-5-(3,4-dimethoxybenzyl)pyrimidine as well as 1 to 100 parts by mass of 2,6-dimethoxy-4-sulfanilamidopyrimidine or a pharmaceutically acceptable salt thereof and 1 to 100 parts by mass of 8-hydroxyquinoline or a pharmaceutically acceptable acid addition salt thereof optionally in admixture with carrier(s) and/or additive(s) commonly used in the pharmaceutical industry or for the preparation of premixes.

摘要翻译： 本发明涉及可用于预防或治愈特别发生在家禽物种上的细菌，真菌和原生动物感染的协同兽药组合物和/或饲料预混物。 此外，本发明涉及其制备方法。 该组合物或预混物含有1〜100质量份的2,4-二氨基-5-（3,4,5-三甲氧基苄基）嘧啶和/或1〜100质量份的2,4-二氨基-5-（3 ，4-二甲氧基苄基）嘧啶，以及1〜100质量份的2,6-二甲氧基-4-磺胺基脒基嘧啶或其药学上可接受的盐和1〜100质量份的8-羟基喹啉或其药学上可接受的酸加成盐 任选地与制药工业中通常使用的载体和/或添加剂混合或用于制备预混物。

公开(公告)号：US20080108673A1

公开(公告)日：2008-05-08

申请号：US11687945

申请日：2007-03-19

申请人： Peter Literati Nagy ,  Zoltan Szilvassy ,  Kalman Tory ,  Laszlo Vigh ,  Kalman Takacs ,  Jozsef Mandl ,  Balazs Sumegi ,  Sandor Bernath ,  Attila Kolonics ,  Gabor Balogh ,  Janos Egri

发明人： Peter Literati Nagy ,  Zoltan Szilvassy ,  Kalman Tory ,  Laszlo Vigh ,  Kalman Takacs ,  Jozsef Mandl ,  Balazs Sumegi ,  Sandor Bernath ,  Attila Kolonics ,  Gabor Balogh ,  Janos Egri

IPC分类号： A61K31/44 ,  A61P3/04

CPC分类号： A61K31/4545 ,  Y10S514/909

摘要： O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or the reduction of the rate of body weight.

摘要翻译： O-（3-哌啶子基-2-羟丙基） - 烟酰胺肟或其药学上合适的酸加成盐（BGP-15）可以用于预防或减轻体重增加或减轻体重。

公开(公告)号：US5240662A

公开(公告)日：1993-08-31

申请号：US827397

申请日：1992-01-29

申请人： Sandor Erdos ,  Denes Bezzegh ,  Janos Egri ,  Erzsebet Barczay ,  Olga Magyar ,  Katalin Sumeg

发明人： Sandor Erdos ,  Denes Bezzegh ,  Janos Egri ,  Erzsebet Barczay ,  Olga Magyar ,  Katalin Sumeg

IPC分类号： A61K9/22 ,  A61K9/20 ,  A61K9/28 ,  A61K31/19 ,  A61K31/195 ,  A61K31/198 ,  A61K47/20 ,  A61K47/38 ,  A61P25/14 ,  C07C229/36 ,  C07C243/18

CPC分类号： A61K9/2077 ,  A61K31/195 ,  A61K9/2004

摘要： The invention relates to a process for the preparation of solid pharmaceutical compositions. More specifically, the invention relates to a process for the preparation of tablets ensuring an increased active ingredient release, where said tablets comprise as active ingredient a mixture of L-3,4-dihydroxyphenylalanine and L-alpha-hydrazino-alpha-methyl-3,4-dihydroxyphenyl propionic acid in a (3-12):1 mass to mass ratio, which comprises admixing any of L-3,4-dihydroxyphenylalanine and L-alpha-hydrazino-alpha-methyl-3,4-dihydroxyphenyl propionic acid, or both of them, with a hydrophilic diluent, preferably lactose and/or microcrystalline cellulose, and optionally with a colouring agent, blending the mixture thus obtained with auxiliary agents conventionally used for the preparation of tablets and optionally with the other active ingredient, furthermore with a solution of stearin in an appropriate solvent, preferably an alkanol comprising 2 to 4 carbon atoms, drying and granulating the mixture thus obtained, optionally admixing further auxiliary agent(s) to the dry granulate, compressing it into tablets comprising 50 to 70% by mass of active ingredient and, if desired, applying a film-coating onto the surface of the tablets thus obtained. The process according to the invention provides tablets of appropriate quality with rapid active ingredient release.

公开(公告)号：US20090214677A1

公开(公告)日：2009-08-27

申请号：US11991362

申请日：2006-08-30

申请人： Péter Literati Nagy ,  Kalman Tory ,  Attila Kolonics ,  Agnes Keri ,  Lajos Laszlo ,  Laszlo Jaszlits ,  Agnes Bajza ,  Sandor Bernath ,  Laszlo Vigh ,  Tibor Bodnar ,  Janos Egri

发明人： Péter Literati Nagy ,  Kalman Tory ,  Attila Kolonics ,  Agnes Keri ,  Lajos Laszlo ,  Laszlo Jaszlits ,  Agnes Bajza ,  Sandor Bernath ,  Laszlo Vigh ,  Tibor Bodnar ,  Janos Egri

IPC分类号： A61K36/28 ,  A61P25/28

CPC分类号： A61K36/28

摘要： An extract of a part of a Solidago species, wherein said part has grown above the earth, or the solid residue remaining after the removal of the solvent content of the extract as the active ingredient is used for the regeneration of the organism of a mammal after long-lasting immobilization, anorexia, states following a disease or accompanied by weight loss as well as for muscle development or muscle growth during muscle developing training, treatment of muscular strain and adaptation to high-altitude as well as for the prevention or treatment of neurodegenerative diseases and/or motility disorders of the gastrointestinal system.

摘要翻译： 一部分单体提取物，其中所述部分已经生长在地球上方，或者在除去作为活性成分的溶剂含量后残留的固体残余物用于哺乳动物的生物再生后 持续的固定化，厌食症，疾病状态或伴随体重减轻以及肌肉发育训练期间的肌肉发育或肌肉生长，肌肉应变治疗和适应高海拔以及预防或治疗神经变性 胃肠系统的疾病和/或运动障碍。